Clinical Efficacy of Darqeen Capsule for the Management of Hypothyroidism Associated with Female Reproductive Hormonal Imbalance
NCT ID: NCT06826248
Last Updated: 2025-02-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
50 participants
INTERVENTIONAL
2024-07-02
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. To assess the safety of Darqeen capsule for the management of Hypothyroidism
2. Evaluate the efficacy of Darqeen capsule for the management of Hypothyroidism
3. To provide an alternative cost-effective treatment for the management of females suffering from hypothyroidism.
NULL HYPOTHESIS (HO) The Unani Medicine Darqeen capsule is not effective for the management of Hypothyroidism.
ALTERNATE HYPOTHESIS (H1) Unani medicine Darqeen capsule is effective for the management of Hypothyroidism.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Low Dose Levothyroxine During Pregnancy
NCT03391154
Thyroxine Therapy for Recurrent Pregnancy Loss in Hypothyroid Women
NCT06036576
Thyroxin in Subclinical Hypothyroidism
NCT03712683
Antithyroidal Antibodies With or Without Subclinical Hypothyroidism During Pregnancy in Infertile Women
NCT04249271
Post Partum Thyroiditis 2: Long Term Observations
NCT00287144
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The prevalence in Pakistan has been a growing concern, necessitating extensive research to address the underlying causes, risk factors, and optimal management strategies. It is estimated that hypothyroidism impacts approximately 5% of the population and 15% in females, with up to 5% possibly having undiagnosed thyroid failure. In Pakistan, the prevalence of hypothyroidism is reported to be 4.1%.
The description of Qillat-e-Ifraz-e-Darqiyya (hypothyroidism) in Unani system of medicine resembles the clinical manifestation associated with Su-e-Mizaj Barid Maddi (derangement in cold temperament).
The management of hypothyroidism involves thyroid hormone replacement therapy with levothyroxine, regular monitoring of hormone levels, and lifestyle modifications like a balanced diet, exercise, and stress management. Iodine supplementation is recommended in iodine-deficient regions, while underlying causes and pregnancy considerations should be managed. Educating patients about their condition and treatment plan is essential for active involvement in their health management.
Darqeen capsule is an Unani polyherbal formulation that primarily consists of natural ingredients, it is time tested pharmacopoeia formulation that is further modified by Hamdard Research Center. It is being used clinically for more than two years at Hamdard Matabs all around Pakistan and found effective for managing hypothyroidism and its associated symptoms.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single Arm
Darqeen Capsule
Effect of Darqeen capsule on Thyroid hormones
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Darqeen Capsule
Effect of Darqeen capsule on Thyroid hormones
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Having raised TSH
* T3 \& T4 hormones level below normal limits
* Females between the age group of 15-45 years
Exclusion Criteria
* Suffering from chronic liver diseases and kidney failure, cancer or any other comorbid condition
* Currently taking any medication for Hypothyroidism or having history of adverse drug reaction
* Pregnant and lactating mothers.
15 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hamdard University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Khadija Shaikh
M Phil Scholar
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shifa Ul Mulk Memorial Hospital-Hamdard University
Karachi, Sindh, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DC-HLWP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.